These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 21214722)

  • 1. Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating β-blockers.
    Deedwania P
    J Clin Hypertens (Greenwich); 2011 Jan; 13(1):52-9. PubMed ID: 21214722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of carvedilol in hypertension: an update.
    Leonetti G; Egan CG
    Vasc Health Risk Manag; 2012; 8():307-22. PubMed ID: 22661898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of beta-blockers on glucose and lipid metabolism.
    Fonseca VA
    Curr Med Res Opin; 2010 Mar; 26(3):615-29. PubMed ID: 20067434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-blocking agents in patients with insulin resistance: effects of vasodilating beta-blockers.
    Jacob S; Balletshofer B; Henriksen EJ; Volk A; Mehnert B; Löblein K; Häring HU; Rett K
    Blood Press; 1999; 8(5-6):261-8. PubMed ID: 10803485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents?
    Jacob S; Rett K; Henriksen EJ
    Am J Hypertens; 1998 Oct; 11(10):1258-65. PubMed ID: 9799045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic properties of vasodilating beta blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome.
    Jacob S; Henriksen EJ
    J Clin Hypertens (Greenwich); 2004 Dec; 6(12):690-6; quiz 697. PubMed ID: 15599117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carvedilol in hypertension treatment.
    Stafylas PC; Sarafidis PA
    Vasc Health Risk Manag; 2008; 4(1):23-30. PubMed ID: 18629377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of vasodilating beta-blockers in patients with hypertension and the cardiometabolic syndrome.
    Taylor AA; Bakris GL
    Am J Med; 2010 Jul; 123(7 Suppl 1):S21-6. PubMed ID: 20609696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of vasodilating beta-blockers on cardiac function and vascular resistance in essential hypertension.
    Lund-Johansen P
    Clin Nephrol; 1992; 38 Suppl 1():S78-86. PubMed ID: 1363538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control.
    Sarafidis PA; Bakris GL
    QJM; 2006 Jul; 99(7):431-6. PubMed ID: 16766516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood pressure control and components of the metabolic syndrome: the GOOD survey.
    Zidek W; Naditch-Brûlé L; Perlini S; Farsang C; Kjeldsen SE
    Cardiovasc Diabetol; 2009 Sep; 8():51. PubMed ID: 19754934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension?
    Sarafidis PA; Bakris GL
    J Clin Hypertens (Greenwich); 2006 May; 8(5):351-6; quiz 357-8. PubMed ID: 16687944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol.
    Marketou M; Gupta Y; Jain S; Vardas P
    Curr Hypertens Rep; 2017 Mar; 19(3):22. PubMed ID: 28283926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-blockers in hypertension.
    Ram CV
    Am J Cardiol; 2010 Dec; 106(12):1819-25. PubMed ID: 21126627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review.
    Carella AM; Antonucci G; Conte M; Di Pumpo M; Giancola A; Antonucci E
    Curr Diabetes Rev; 2010 Jul; 6(4):215-21. PubMed ID: 20459394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha blockers and vasodilating beta blockers--influence on factors involved in the pathogenesis of vascular disease in patients with hypertension.
    Louis WJ; Drummer OH; Howes LG
    Clin Exp Hypertens A; 1989; 11(5-6):1075-83. PubMed ID: 2571433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol.
    Bakris GL; Basile JN; Giles TD; Taylor AA
    Am J Med; 2010 Jul; 123(7 Suppl 1):S2-8. PubMed ID: 20609695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arterial stiffness, hypertension, and rational use of nebivolol.
    Agabiti-Rosei E; Porteri E; Rizzoni D
    Vasc Health Risk Manag; 2009; 5(1):353-60. PubMed ID: 19475771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of obesity hypertension and diabetes syndrome.
    Zanella MT; Kohlmann O; Ribeiro AB
    Hypertension; 2001 Sep; 38(3 Pt 2):705-8. PubMed ID: 11566961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasodilating versus first-generation β-blockers for cardiovascular protection.
    Fares H; Lavie CJ; Ventura HO
    Postgrad Med; 2012 Mar; 124(2):7-15. PubMed ID: 22437211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.